NYSE:NAVB Navidea Biopharmaceuticals (NAVB) Stock Price, News & Analysis → Gold Prices Surge and This $0.32 Stock Is Reaping The Rewards (From Market JAR) (Ad) Free NAVB Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range$0.00▼$0.0552-Week Range N/AVolumeN/AAverage Volume41,689 shsMarket Capitalization$10,000.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends Get Navidea Biopharmaceuticals alerts: Email Address Ad Market JARGold Prices Surge and This $0.32 Stock Is Reaping The RewardsGold prices are on the rise. This surge in gold prices is great news for gold mining stocks. Especially for a $0.32 gold producer that's flying under the radar.Here's what you need to know about this $0.32 gold producer. About Navidea Biopharmaceuticals Stock (NYSE:NAVB)Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.Read More Ad Market JARGold Prices Surge and This $0.32 Stock Is Reaping The RewardsGold prices are on the rise. This surge in gold prices is great news for gold mining stocks. Especially for a $0.32 gold producer that's flying under the radar.Here's what you need to know about this $0.32 gold producer. NAVB Stock News HeadlinesJune 8, 2024 | americanbankingnews.comNavidea Biopharmaceuticals (NYSE:NAVB) Research Coverage Started at StockNews.comMay 25, 2024 | wsj.comSK Biopharmaceuticals Co. Ltd.May 3, 2024 | nasdaq.comDay One Biopharmaceuticals, Inc. Common Stock (DAWN)February 23, 2024 | benzinga.comNavidea Biopharmaceutical Stock (OTC:NAVB), Short Interest ReportFebruary 22, 2024 | benzinga.comNavidea Biopharmaceutical Stock (OTC:NAVB) Dividends: History, Yield and DatesFebruary 22, 2024 | benzinga.comNavidea Biopharmaceutical Stock (OTC:NAVB) Insider TradesJanuary 29, 2024 | bizjournals.comCentral Ohio public company voluntarily deregisters stockJanuary 26, 2024 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting ObligationsJanuary 26, 2024 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting ObligationsJanuary 11, 2024 | investing.comSuzhou Zelgen Biopharmaceuticals Co Ltd (688266)December 1, 2023 | msn.comNavidea settles litigation with Capital Royalty, stock rallies 30%December 1, 2023 | markets.businessinsider.comNavidea Biopharmaceuticals, CRG Settle All Ongoing LitigationNovember 1, 2023 | morningstar.comNavidea Biopharmaceuticals Inc NAVBOctober 26, 2023 | investing.comNavidea Biopharmaceuticals faces delisting from NYSE American, plans to move to OTC marketsOctober 6, 2023 | bizjournals.comNYSE American halts trading on Navidea stock after delisting recommendedOctober 5, 2023 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common StockOctober 5, 2023 | tmcnet.comNYSE American to Suspend Trading in Navidea Biopharmaceuticals, Inc. (NAVB)August 10, 2023 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing PanelAugust 1, 2023 | finance.yahoo.comNYSE American starts to delist Navidea stock, company to appealJuly 31, 2023 | benzinga.comWhy Navidea Biopharmaceuticals Shares Are NosedivingJuly 31, 2023 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Presses Ahead, Embraces OpportunitiesJuly 28, 2023 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American DeterminationJuly 28, 2023 | businesswire.comNYSE American to Commence Delisting Proceedings Against Navidea Biopharmaceuticals, Inc. (NAVB)July 28, 2023 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial OfficerJuly 13, 2023 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps DownSee More Headlines Receive NAVB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today6/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolNYSE:NAVB CUSIPN/A CIK810509 Webwww.navidea.com Phone614-793-7500Fax614-793-7522Employees11Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,180,000.00 Net MarginsN/A Pretax Margin-860,700.00% Return on EquityN/A Return on Assets-166.65% Debt Debt-to-Equity RatioN/A Current Ratio0.56 Quick Ratio0.51 Sales & Book Value Annual Sales$8,126.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.25) per share Price / BookN/AMiscellaneous Outstanding Shares100,084,000Free Float56,367,000Market Cap$10,000.00 OptionableOptionable Beta0.76 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Michael Sherman Blue F.A.C.E.P.M.D., Chief Medical OfficerKey CompetitorsIDEXX LaboratoriesNASDAQ:IDXXLantheusNASDAQ:LNTHNeogenNASDAQ:NEOGQuidelOrthoNASDAQ:QDELCelldex TherapeuticsNASDAQ:CLDXView All Competitors NAVB Stock Analysis - Frequently Asked Questions How were Navidea Biopharmaceuticals' earnings last quarter? Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.03. The company earned $0.10 million during the quarter, compared to the consensus estimate of $0.60 million. How do I buy shares of Navidea Biopharmaceuticals? Shares of NAVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:NAVB) was last updated on 6/13/2024 by MarketBeat.com Staff From Our PartnersTrump Warns Gov. Can Confiscate Your Money. CBDC's give Gov. absoluteDonald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans...Monetary Gold | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | SponsoredGold Prices Surge and This $0.32 Stock Is Reaping The RewardsGold prices are on the rise. This surge in gold prices is great news for gold mining stocks. Especially ...Market JAR | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredWall Street Icon: "I'd Put 50% of My Kids' Inheritance in THIS stock"Wall Street Icon Warns: "A Great Financial Reset is Underway" The man CNBC called "The Prophet" predicted t...Stansberry Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Navidea Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.